FDA approves Hovilpri for immunocompromised patients with HSV lesions
The FDA approved Hovilpri (pritelivir) tablets for adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus and have not responded to acyclovir, valacyclovir, or famciclovir. In a Phase 3 trial, 63% of patients treated with Hovilpri had all lesions healed by 28 days versus 34% with other medications.
Primary source
FDA approval notification, October 9, 2026
FDA Approves Drug to Treat Lesions Caused by Herpes Simplex Virus
Read the source: FDA Approves Drug to Treat Lesions Caused by Herpes Simplex Virus fda.gov
Machine-summarized from the source above; not independently reported. How we use automation